Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many dosing/administration and labeled safety contraindication statements align with the provided label text, including weekly injection schedule, injection sites, titration steps, missed-dose rule, and boxed warning theme. However, multiple claims are unsupported or conflict with the provided label text, notably the “needle angle 90 degrees” instruction, the “dose button until counter shows 0 mg” and “leave needle 5–10 seconds” instructions, adverse reaction percentages, and pregnancy/breastfeeding cautions that are partially inconsistent with the provided label excerpts (especially lactation vs. injection vs. tablets).
Category Scores
Accurate Statements
Wegovy is administered by weekly subcutaneous injection.
2.1: “Administer WEGOVY injection once weekly, on the same day each week… with or without meals.”
Wegovy injection sites include the abdomen, thigh, or upper arm.
2.1: “Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm.”
Wegovy should be injected on the same day each week.
2.1: “Administer WEGOVY injection once weekly, on the same day each week…”
Wegovy can be administered with or without meals.
2.1: “…at any time of day, with or without meals.”
The recommended starting dosage for Wegovy injection is 0.25 mg once weekly.
2.2: “The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly.”
After weeks 1-4, Wegovy is increased to 0.5 mg once weekly for weeks 5-8.
Table 1: “1 through 4: 0.25 mg”; “5 through 8: 0.5 mg.”
After weeks 5-8, Wegovy is increased to 1 mg once weekly for weeks 9-12.
Table 1: “9 through 12: 1 mg.”
After weeks 9-12, Wegovy is increased to 1.7 mg once weekly for weeks 13-16.
Table 1: “13 through 16: 1.7 mg.”
Wegovy injection missed-dose rule: if next scheduled dose is more than 2 days away, administer as soon as possible; if less than 2 days away, do not administer and resume on regularly scheduled day.
2.4: “…more than 2 days away, administer… as soon as possible”; “…less than 2 days away, do not administer… Resume dosing on the regularly scheduled day of the week.”
Wegovy injection should be rotated among injection sites with each dose.
2.1: “Rotate injection sites with each dose.”
Wegovy is contraindicated in patients with personal or family history of MTC or in MEN 2.
4 Contraindications: “a personal or family history of MTC or in patients with MEN 2”
Wegovy is contraindicated in patients with a prior serious hypersensitivity reaction to semaglutide or excipients in the WEGOVY injection/tablet.
4 Contraindications: “a prior serious hypersensitivity reaction to semaglutide or… excipients in WEGOVY injection or WEGOVY tablet.”
Wegovy boxed warning concerns thyroid C-cell tumors, including unknown relevance to humans and contraindication in MTC/MEN 2.
Boxed Warning section 4/WARNING: “Risk of Thyroid C-cell Tumors” and “WEGOVY is contraindicated…”
Wegovy should be discontinued and medical help sought for acute pancreatitis symptoms such as persistent or severe abdominal pain (sometimes radiating to the back), with or without nausea/vomiting; discontinue if pancreatitis is suspected.
5.2: “After initiation… observe… for signs and symptoms of acute pancreatitis… persistent or severe abdominal pain… If pancreatitis is suspected, discontinue WEGOVY…”
Wegovy is associated with increased occurrence of cholelithiasis and cholecystitis (gallbladder problems).
5.3: “Treatment with WEGOVY is associated with an increased occurrence of cholelithiasis and cholecystitis.”
Wegovy can cause hypoglycemia and this risk is increased when used with insulin or insulin secretagogues; monitor blood glucose in patients with diabetes.
5.4: “WEGOVY lowers blood glucose and can cause hypoglycemia… risk… increased… with insulin or an insulin secretagogue… In patients with diabetes… monitor blood glucose…”
Patients should be informed to stop WEGOVY and seek medical advice promptly for hypersensitivity reactions (e.g., anaphylaxis/angioedema).
5.7: “…If hypersensitivity reactions occur, discontinue use of WEGOVY… Serious hypersensitivity reactions… have been reported…” and counseling text in 17.
Unsupported Statements
The needle should be inserted straight into the skin at a 90-degree angle.
No 90-degree needle-angle instruction appears in the provided label excerpts (2.1/Instructions for Use section content not included here).
The dose button should be pressed fully until the counter shows 0 mg.
No such counter-to-0 mg instruction is present in the provided label excerpts.
After injecting Wegovy, the needle should be left in the skin for 5 to 10 seconds to ensure the full dose delivers.
No 5–10 second needle dwell-time instruction appears in the provided label excerpts.
Wegovy pens should not be reused and should be disposed of in a sharps container after use.
The provided label excerpts do not include reuse/disposal instructions for pens.
Wegovy pens are color-coded by dose strength for easy identification.
No color-coding statement is present in the provided label excerpts.
Wegovy pens should be kept in the refrigerator at 36-46°F (2-8°C) until first use.
Storage temperature details are not included in the provided label excerpts.
After first use, Wegovy pens can be stored at room temperature (up to 86°F or 30°C) for up to 28 days or refrigerated.
Storage-after-first-use time/temperature details are not included in the provided label excerpts.
Wegovy pens should not be frozen or exposed to heat or excessive light.
No such specific storage/handling restrictions are present in the provided label excerpts.
Each Wegovy pen delivers 4 weekly doses.
No statement about “4 weekly doses per pen” appears in the provided excerpts for pens. The label excerpts show “Single-Patient-Use Pen (4 doses per Pen) (WEGOVY FlexTouch)” but the claim is phrased for “Wegovy pens” generally (not distinguishing FlexTouch).
Wegovy should be discarded after use even if liquid remains.
No disposal-after-use-even-if-liquid-remains instruction is present in the provided label excerpts.
Common Wegovy side effects include nausea, diarrhea, vomiting, constipation, and stomach pain.
The provided label excerpts discuss gastrointestinal adverse reactions generally and severe GI adverse reactions, but do not list these specific items as “common” or provide that set in a common-adverse-reaction sentence.
These common side effects affect over 20% of users.
No “over 20%” prevalence statement for those GI effects is present in the provided label excerpts.
Wegovy should be stopped and medical help sought for vision changes.
The provided label excerpts include counseling to contact physician for “changes in vision,” but the instruction to stop Wegovy specifically for vision changes is not shown in the provided excerpts.
Wegovy should not be used in people with a history of pancreatitis.
The provided excerpts include pancreatitis warning/counseling, but do not state a contraindication or “should not be used” for history of pancreatitis.
Patients should inform their doctor of kidney or liver issues before using Wegovy.
No kidney/liver issue counseling statement appears in the provided excerpts.
Patients should inform their doctor of heart problems before using Wegovy.
No “heart problems” statement appears in the provided excerpts, though there is counseling about informing about palpitations/racing heartbeat.
Wegovy should be combined with a 500-calorie daily deficit diet and at least 150 minutes of exercise per week.
Label excerpts state approximately 500 kcal/day deficit and recommended minimum 150 min/week as counseling in Studies, but the provided sections frame this as study instruction/counseling, not as a prescriptive requirement for use. This is not explicitly stated as a required “should be combined” regimen in the provided excerpts.
In trials, Wegovy resulted in 15-20% body weight loss over 68 weeks.
The provided excerpts show study outcomes but do not provide a summary statement “15-20% body weight loss over 68 weeks.” (Table values shown are percent change, but the aggregate 15–20% range is not explicitly stated as such.)
Results with Wegovy vary.
No such general statement appears in the provided label excerpts.
Wegovy should be discontinued if there is no weight loss after 12 weeks on the 2.4 mg dose.
The provided label excerpts do not include a discontinuation criterion based on lack of weight loss after 12 weeks on 2.4 mg.
Compounded versions of semaglutide are not FDA approved.
The provided label excerpts do not address compounded semaglutide approval status.
Savings cards from Novo Nordisk cap copays at $25/month for eligible commercially insured patients (up to 13 fills).
The provided label excerpts do not include copay/savings card terms or $25/month/13 fills.
A month’s supply of Wegovy at the maintenance dose costs $1,300-$1,700 without insurance.
The provided label excerpts do not include pricing information.
Contradictions
Low
AI Statement
Wegovy should be avoided during pregnancy because it may harm the fetus.
Label Reference
8.1 Pregnancy: “Weight loss offers no benefit… and may cause fetal harm. When a pregnancy is recognized… Discontinue WEGOVY in pregnant patients who are using it for weight reduction.” and “Based on animal reproduction studies, there may be potential risks…” (provided label does not frame this as a blanket “avoid during pregnancy” statement).
Low
AI Statement
Wegovy should be avoided during breastfeeding.
Label Reference
8.2 Lactation (provided excerpts): For subcutaneous injection, “There are no data on the presence of subcutaneously administered semaglutide… WEGOVY subcutaneous injection does not contain the SNAC metabolites.” (it does not state “avoid during breastfeeding” for injection in the provided excerpt). Counseling text in 17 references breastfeeding not explicitly for injection.
Important Omissions
Indication breadth was only partially covered: label excerpt includes additional injection indication to reduce risk of major adverse cardiovascular events in adults with established CV disease and obesity/overweight, and includes noncirrhotic MASH (accelerated approval) for adults; also pediatric indication (obesity in patients aged 12+).
Importance:
Moderate
Important administration detail: visually inspect solution for clarity/colorlessness/no particles prior to each administration; rotate injection sites (rotation mentioned but visual inspection not included).
Importance:
Moderate
Dose selection at maintenance: label indicates cardiovascular risk reduction maintenance dosage is either 2.4 mg (recommended) or 1.7 mg once weekly; weight reduction maintenance is either 1.7 mg or 2.4 mg (recommended). The claims only state one maintenance trajectory to 2.4 mg, without acknowledging alternative maintenance options.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several injection technique/pen-handling details are unsupported (needle angle, press-to-0 mg, dwell time, disposal/reuse), and some safety-related statements are unsupported or incompletely aligned (vision change stop instruction, pancreatitis history as avoidance). Lactation guidance is partially inconsistent with the provided excerpt differentiation (tablets vs subcutaneous injection). These issues could lead to incorrect administration or misunderstanding of pregnancy/lactation counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple administration technique, storage/handling, adverse reaction prevalence, and population guidance claims are either unsupported or inconsistent with the provided label excerpts.
Suggested Improvement
Remove or rephrase unsupported technique/storage/pen-handling and prevalence claims unless the label excerpts include them; differentiate lactation counseling for subcutaneous injection vs tablets; restrict pregnancy statements to the label’s “discontinue when recognized for weight reduction” framework; add the missing labeled indications and any key administration checks (e.g., visual inspection) as present in the provided label.